NFE2L2 and ovarian cancer: These findings suggested that while retinoids/rexinoids, like retinoic acid (RA) and bexarotene, inhibit the NRF2-dependent AR pathway, such treatment might also elevate cellular ROS levels in the ovarian cancer cell lines.